GVS assessment of amisulpride (Aktiprol®) for the treatment of schizophrenia
The National Health Care Institute has completed its assessment whether the product amisulpride (Aktiprol®) can be included in the Medicine Reimbursement System (GVS). Based on the criteria for interchangeability, it can be concluded that amisulpride (Aktiprol®) is interchangeable with the other medicinal products in the GVS. The National Health Care Institute's advice is to include amisulpride (Aktiprol®) on List 1A of the GVS in cluster group 4N05***O V.
Interchangeability
Based on the criteria for interchangeability, it can be concluded that amisulpride (Aktiprol®) is interchangeable with the other medicinal products in the GVS cluster group 4N05***O V, which includes aripiprazole (Abilify®), cariprazine (Reagila®), lurasidone (Latuda®), olanzapine (Zyprexa®), paliperidone (Invega®), quetiapine (Seroquel®), risperidone (Risperdal®), sertindole (Serdolect®) and sulpiride (Dogmatil®).
The National Health Care Institute's advice
The National Health Care Institute advices the Minister for Medical Care to include include amisulpride (Aktiprol®) in the GVS on List 1A in cluster group 4N05***O V. 400 mg can be used as the standard dose. Amisulpride (N05AL05) has an ATC code that is comparable to that of sulpiride (N05AL01).